Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07721025
PHASE2

Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy

Sponsor: Lexeo Therapeutics

View on ClinicalTrials.gov

Summary

The purpose of Study LX2006-03, a multicenter, Phase 2, open-label, randomized, controlled study, is to evaluate the efficacy and safety of LX2006 gene therapy in participants with Friedreich ataxia (FA) cardiomyopathy (CM).

Official title: A Phase 2, Multicenter, Open-label, Randomized, Controlled Study of LX2006 Gene Therapy in Participants With Friedreich Ataxia Cardiomyopathy (SUNRISE-FA 2)

Key Details

Gender

All

Age Range

6 Years - Any

Study Type

INTERVENTIONAL

Enrollment

26

Start Date

2026-06-25

Completion Date

2032-06

Last Updated

2026-07-22

Healthy Volunteers

No

Interventions

GENETIC

LX2006

Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)

OTHER

Usual Care

Cohort 1: Participants ≥16 years of age with FA-CM Participants will receive usual care for 26 weeks before receiving treatment with LX2006 (single crossover).

Locations (1)

University of South Florida

Tampa, Florida, United States